Avian Influenza A (H7N9) Threatens, GenScript Supports Researchers in Impending Battle with Rush Gene Service
Piscataway, NJ April 5, 2013
This week the World Health Organization reported 3 cases in which humans were infected with Avian Influenza A (H7N9) Virus in China. These are the first reports ever in which the H7N9 strain has been shown to have infected humans. Currently, it is unclear whether or not the virus can be spread via human-to-human contact, however genetic sequences for the virus have been published, and the Center for Disease Control has already reported the start of vaccine development for the virus.
The foundation of vaccine development is often the identification and re-construction of the parts of the viral genome sequence that encode for antigens capable of eliciting the necessary immune response that, upon infection, will fight the live virus. Gene synthesis is a powerful tool for vaccine development, enabling the rapid construction of any vector expressing an antigen capable of eliciting the necessary immune response to fight infection.
GenScript is committed to arming researchers with the necessary custom bioreagents, such as synthetic DNA, to accelerate the research that will prevent the spread of disease. As proof of this commitment, GenScript recently became the fastest global biotech company to complete synthesis of a key H7N9-related gene on April 5th, in only 4 days, using our Rush Gene Synthesis Service. In the effort to accelerate critical H7N9 research, GenScript has now synthesized over 30 crucial H7N9-related genes in our collaborations with prestigious institutions including the NIH, CDC, and Chinese Academy of Science, as well as leading vaccine centers in the United States and research organizations in Hong Kong and Japan.
Whether or not an H7N9 outbreak will occur remains to be seen, but at GenScript, we know that the best way to prevent the spread of disease, is to be prepared. Together, we can save lives!
*GenScript follows strict regulatory compliance procedures when synthesizing https://essaywriterguide.com/ and delivering any type of DNA sequence known to encode for infectious disease. End users of these sequences must have appropriate regulatory clearances.
GenScript is the leading gene, peptide, protein and antibody research partner for fundamental life science research, translational biomedical research, and early stage pharmaceutical development. Since our establishment in 2002, GenScript has exponentially grown to become a global leading biotech company that provides life sciences services and products to scientists over 100 countries worldwide. During our tenure we have built the best-in-class capacity and capability for biological research services encompassing gene synthesis and molecular biology, peptide synthesis, custom antibodies, protein expression, antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.